Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study

• Status: Completed
• Trial end date: 2018-10-22
• Target enrollment: 0
• Participant gender: All

Summary

This prospective study will assess Ozurdex in the treatment of Diabetic Macular Oedema in clinical practice.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate

Criteria

Inclusion Criteria:

• Pseudophakic or phakic and scheduled for a cataract operation

• Macular oedema due to DME

Exclusion Criteria:

• Previous Ozurdex® treatment